Impact of 6- versus 12-month dual antiplatelet therapy on clinical prognosis in patients with high bleeding risk: Insights from the 4-year results of the I LOVE IT 2 study.

Jiaoyang ZhangMiaohan QiuKun NaSicong MaZaixin JiangJing LiYi LiYa-Ling Han

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)

HBR patients are at a higher risk of long-term bleeding and ischemic events than non-HBR patients. The safety and efficacy of 6- and 12-month DAPT were comparable in HBR patients.

Keyphrases

end stage renal disease
newly diagnosed
antiplatelet therapy
ejection fraction
chronic kidney disease
prognostic factors
atrial fibrillation
oxidative stress
coronary artery disease
brain injury